GERAS-USNCT02951598
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 28 versions: 19 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Final enrollment: 1198 participants (planned 1400)
- Study completion date changed from estimate of Apr 28, 2026 to Jan 30, 2021
- Minor Study completion date: Apr 28, 2023 to Apr 28, 2026v26
- Notable Phase: Not applicable to Not specifiedv25
- Minor Primary completion date changed from estimate of Jan 22, 2021 to Jan 30, 2021v24
- Minor Primary completion date: Oct 28, 2020 to Jan 22, 2021
- Study completion date: Oct 28, 2020 to Apr 28, 2023
Show 14 earlier versionsHide 14 earlier versions
- Minor Study sites: 84 to 77v16
- Minor Primary completion date: Oct 2020 to Oct 28, 2020
- Study completion date: Oct 2025 to Oct 28, 2020
- Start date: Oct 2016 to Oct 29, 2016
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 91 to 84
- Minor Study sites: 86 to 91v13
- Minor Study sites revised (86)v12
- Minor Study sites: 79 to 86v11
- Minor Study sites: 81 to 79v10
- Minor Study sites: 79 to 81v9
- Minor Study sites: 78 to 79v8
- Minor Study sites: 74 to 78v7
- Minor Study sites: 46 to 74v6
- Minor Study sites revised (46)v5
- Minor Study sites: 47 to 46v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 47
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
Drugs: Florbetapir F 18 PET Scan
Sites
77 sites in 1 country